Cytochrome P450 1B1 (CYP1B1) Pharmacogenetics: Association of Polymorphisms with Functional Differences in Estrogen Hydroxylation Activity
IH Hanna, S Dawling, N Roodi, FP Guengerich, FF Parl - Cancer research, 2000 - AACR
Activation of 17β-estradiol (E2) through the formation of catechol estrogen metabolites, 2-OH-E2
and 4-OH-E2, and the C-16αhydroxylation product, 16α-OH-E2, has been postulated to …
and 4-OH-E2, and the C-16αhydroxylation product, 16α-OH-E2, has been postulated to …
Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium
…, A Galetin, KM Giacomini, I Hanna… - Clinical …, 2018 - Wiley Online Library
Drug transporters can govern the absorption, distribution, metabolism, and excretion of
substrate drugs and endogenous substances. Investigations to examine their potential impact to …
substrate drugs and endogenous substances. Investigations to examine their potential impact to …
Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH-and hydroperoxide-supported activities
IH Hanna, JF Teiber, KL Kokones… - Archives of Biochemistry …, 1998 - Elsevier
Escherichia coliwas used to express the two closely related cytochromes P450 2B1 and 2B2
and two mutants of 2B2 in which residues Gly-303 and Ala-363 were replaced by Ser and …
and two mutants of 2B2 in which residues Gly-303 and Ala-363 were replaced by Ser and …
Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk …
…, M Brännström, X Chu, C Funk, A Guo, I Hanna… - Drug metabolism and …, 2013 - ASPET
A P-glycoprotein (P-gp) IC 50 working group was established with 23 participating
pharmaceutical and contract research laboratories and one academic institution to assess …
pharmaceutical and contract research laboratories and one academic institution to assess …
Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli
RB Vail, MJ Homann, I Hanna… - Journal of Industrial …, 2005 - academic.oup.com
Three human cytochrome P450s, 3A4, 2C9 and 1A2, were each co-expressed with NADPH-P450
reductase in Escherichia coli and used in the preparative synthesis of drug metabolites…
reductase in Escherichia coli and used in the preparative synthesis of drug metabolites…
Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver
IH Hanna, JR Reed, FP Guengerich… - Archives of Biochemistry …, 2000 - Elsevier
Expression of human cytochrome P450 (P450) 2B6 in Escherichia coli was achieved
following supplementation of the expression medium with chloramphenicol. The recombinant …
following supplementation of the expression medium with chloramphenicol. The recombinant …
Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects
…, N Alexander, A Vapurcuyan, I Hanna… - European journal of …, 2012 - Springer
Purpose To conduct a mechanistic investigation of the interaction between aliskiren and
grapefruit juice in healthy subjects. Methods Twenty-eight subjects received an oral dose of …
grapefruit juice in healthy subjects. Methods Twenty-eight subjects received an oral dose of …
Clinical relevance of hepatic and renal P‐gp/BCRP inhibition of drugs: An international transporter consortium perspective
…, Y Sugiyama, J Cook, JW Polli, I Hanna… - Clinical …, 2022 - Wiley Online Library
The role of P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) in drug–drug
interactions (DDIs) and limiting drug absorption as well as restricting the brain penetration …
interactions (DDIs) and limiting drug absorption as well as restricting the brain penetration …
A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters
…, B Poller, N Domange, R de Wilde, I Hanna… - Drug Metabolism and …, 2019 - ASPET
Preincubation of a drug transporter with its inhibitor in a cell-based assay may result in the
apparent enhancement of the inhibitory potency. Currently, limited data are available on …
apparent enhancement of the inhibitory potency. Currently, limited data are available on …
Recombinant Human Cytochrome P450 1B1 Expression inEscherichia coli
T Shimada, RM Wunsch, IH Hanna, TR Sutter… - Archives of Biochemistry …, 1998 - Elsevier
Human cytochrome P450 (P450) 1B1 was expressed inEscherichia coliat a level of 200
nmol/liter culture using a pCW vector by removal of codons 2–4 and modification of the …
nmol/liter culture using a pCW vector by removal of codons 2–4 and modification of the …